Amedisys Inc (AMED): Price and Financial Metrics


Amedisys Inc (AMED)

Today's Latest Price: $240.67 USD

5.49 (2.33%)

Updated Nov 27 1:00pm

Add AMED to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 70 in Medical - Services

See all "A" rated Strong Buy stocks

AMED Stock Summary

  • AMED has a market capitalization of $7,896,512,421 -- more than approximately 81.15% of US stocks.
  • AMED's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 454.12 -- higher than 92.51% of US-listed equities with positive expected earnings growth.
  • Price to trailing twelve month operating cash flow for AMED is currently 26.48, higher than 83.81% of US stocks with positive operating cash flow.
  • If you're looking for stocks that are quantitatively similar to Amedisys Inc, a group of peers worth examining would be EHC, USM, EXPD, MORN, and RS.
  • AMED's SEC filings can be seen here. And to visit Amedisys Inc's official web site, go to www.amedisys.com.

AMED Stock Price Chart Interactive Chart >

Price chart for AMED

AMED Price/Volume Stats

Current price $240.67 52-week high $273.77
Prev. close $235.18 52-week low $132.95
Day low $234.72 Volume 53,400
Day high $240.67 Avg. volume 267,846
50-day MA $244.65 Dividend yield N/A
200-day MA $210.30 Market Cap 7.90B

Amedisys Inc (AMED) Company Bio


Amedisys provides home health and hospice care services. It operates through two segments, Home Health and Hospice. The company was founded in 1982 and is based in Baton Rouge, Louisiana.

AMED Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$240.67$283.93 18%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Amedisys Inc. To summarize, we found that Amedisys Inc ranked in the 50th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 18.33% on a DCF basis. In terms of the factors that were most noteworthy in this DCF analysis for AMED, they are:

  • The company's debt burden, as measured by earnings divided by interest payments, is 16.91 -- which is good for besting 78.16% of its peer stocks (US stocks in the Healthcare sector with positive cash flow).
  • The business' balance sheet reveals debt to be 5% of the company's capital (with equity being the remaining amount). Approximately merely 15.17% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
  • AMED's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 43.83% of tickers in our DCF set.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%15%
1%17%
2%18%
3%19%
4%20%
5%21%

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as AMED, try EGRX, INBP, QDEL, SNY, and LCI.


AMED Latest News Stream


Event/Time News Detail
Loading, please wait...

AMED Latest Social Stream


Loading social stream, please wait...

View Full AMED Social Stream

Latest AMED News From Around the Web

Below are the latest news stories about Amedisys Inc that investors may wish to consider to help them evaluate AMED as an investment opportunity.

Amedisys inks agreement with BrightStar Care

Amedisys (AMED) signed a Care Coordination Agreement with BrightStar Care in order to add its agencies to the Amedisys Personal Care Network and facilitate the coordination of care between the former's hospice and home health care centers and personal care partners network.BrightStar Care’s 340 personal care locations in 38 states...

Seeking Alpha | August 24, 2020

Amedisys, Inc. (AMED) CEO Paul Kusserow on Q2 2020 Results - Earnings Call Transcript

Amedisys, Inc. (AMED) Q2 2020 Earnings Conference Call July 29, 2020 11:00 AM ET Company Participants Nick Muscato - Vice President of Strategic Finance Paul Kusserow - President & Chief Executive Officer Scott Ginn - Chief Financial Officer Chris Gerard - Chief Operating Officer Conference Call Participants Brian Tanquilut -...

SA Transcripts on Seeking Alpha | July 30, 2020

Amedisys Reports Second Quarter 2020 Financial Results - Reissues 2020 Guidance

BATON ROUGE, La., July 28, 2020 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and six-month period…

GlobeNewswire | July 28, 2020

Why Earnings Season Could Be Great for Amedisys (AMED)

Amedisys (AMED) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Yahoo | July 27, 2020

Stocks To Watch With Earnings On Deck: Amedisys

Amedisys (AMED) is expected to report earnings on Jul. 28. Amedisys now trading 2% below the 218.54 buy point from a fourth-stage consolidation that it cleared earlier. Understand that it's risky to buy any stock just before it reports. You can reduce your risk by waiting to see the actual numbers and the market's reaction. Looking For The Best Stocks...

Yahoo | July 24, 2020

Read More 'AMED' Stories Here

AMED Price Returns

1-mo -7.08%
3-mo -0.51%
6-mo 26.66%
1-year 47.69%
3-year 345.69%
5-year 481.19%
YTD 44.18%
2019 42.53%
2018 122.18%
2017 23.65%
2016 8.42%
2015 33.97%

Continue Researching AMED

Here are a few links from around the web to help you further your research on Amedisys Inc's stock as an investment opportunity:

Amedisys Inc (AMED) Stock Price | Nasdaq
Amedisys Inc (AMED) Stock Quote, History and News - Yahoo Finance
Amedisys Inc (AMED) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8358 seconds.